Shehzad Topiwala, MD
Endocrinology, Diabetes & Metabolism · Stockbridge, GANPI 1164684700
Payments from drug & device makers
Across 792 payments — averaging $216.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$49K
- Eli Lilly$47K
- Astrazeneca UK Limited$31K
- Sanofi US Services Inc.$18K
- Xeris Pharmaceuticals, Inc.$4K
- Sanofi-aventis U.S. LLC$4K
- plus $19K from 54 others
Across 3 payments — averaging $781.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Consulting fees$9,55134%
- Speaking & faculty fees$2001%
- Travel & lodging$480%
- Food & beverage$18,16865%
- Education$1581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$171,790 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 425 | $540,139 |
| MounjaroTirzepatide | 258 | $311,065 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 231 | $253,876 |
| JardianceEmpagliflozin | 162 | $185,717 |
| Gvoke Hypopen 2-PackGlucagon | 155 | $100,840 |
| Tresiba Flextouch U-200Insulin Degludec | 114 | $90,168 |
| FarxigaDapagliflozin Propanediol | 58 | $75,657 |
| TradjentaLinagliptin | 73 | $71,264 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $60,563 |
| JanuviaSitagliptin Phosphate | 45 | $53,730 |
| TrulicityDulaglutide | 38 | $47,594 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 64 | $43,677 |
| Humalog Kwikpen U-200Insulin Lispro | 43 | $42,041 |
| NovologInsulin Aspart | 94 | $30,020 |
| Omnipod 5 Dexg7g6 Intro(Gen 5)Insulin Pmp Cart,aut,g6/7,cntr | 46 | $26,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Rybelsus | $3,015 | $588,846534 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $2,924 | $378,485395 claims |
| Boehringer IngelheimJardiance, Tradjenta | $466 | $256,981235 claims |
| AstraZenecaFarxiga | $321 | $75,65758 claims |
| MerckJanuvia, Janumet | $223 | $73,30461 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,786 | $25,40415 claims |
| AmgenProlia | $1,880 | $23,83014 claims |
| AbbVieSynthroid | $328 | $15,605168 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $496 | $5,135516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Stockbridge
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
- Thomas ZieglerAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.